Equities research analysts expect Evolent Health Inc (NYSE:EVH) to announce sales of $192.57 million for the current fiscal quarter, according to Zacks. Ten analysts have provided estimates for Evolent Health’s earnings. The highest sales estimate is $195.00 million and the lowest is $189.80 million. Evolent Health posted sales of $144.51 million in the same quarter last year, which suggests a positive year-over-year growth rate of 33.3%. The firm is scheduled to announce its next earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Evolent Health will report full year sales of $838.07 million for the current fiscal year, with estimates ranging from $826.33 million to $846.41 million. For the next financial year, analysts forecast that the firm will post sales of $947.17 million, with estimates ranging from $925.50 million to $986.68 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Evolent Health.
Evolent Health (NYSE:EVH) last released its earnings results on Tuesday, May 7th. The technology company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.02. The company had revenue of $197.80 million for the quarter, compared to the consensus estimate of $192.65 million. Evolent Health had a negative return on equity of 4.80% and a negative net margin of 12.52%. Evolent Health’s quarterly revenue was up 41.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.02 earnings per share.
Hedge funds have recently modified their holdings of the company. Parkside Financial Bank & Trust increased its holdings in shares of Evolent Health by 57.7% in the fourth quarter. Parkside Financial Bank & Trust now owns 3,628 shares of the technology company’s stock worth $72,000 after purchasing an additional 1,327 shares during the last quarter. We Are One Seven LLC bought a new stake in shares of Evolent Health in the fourth quarter worth about $99,000. Jane Street Group LLC bought a new stake in shares of Evolent Health in the third quarter worth about $205,000. Great West Life Assurance Co. Can increased its holdings in shares of Evolent Health by 42.3% in the first quarter. Great West Life Assurance Co. Can now owns 8,754 shares of the technology company’s stock worth $110,000 after purchasing an additional 2,604 shares during the last quarter. Finally, GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in shares of Evolent Health in the first quarter worth about $141,000. 99.96% of the stock is currently owned by hedge funds and other institutional investors.
NYSE:EVH traded down $0.18 on Tuesday, reaching $14.19. 95,340 shares of the company’s stock traded hands, compared to its average volume of 826,189. The company has a quick ratio of 1.96, a current ratio of 1.96 and a debt-to-equity ratio of 0.24. The stock has a market cap of $1.17 billion, a PE ratio of -40.54 and a beta of 1.26. Evolent Health has a 12 month low of $12.09 and a 12 month high of $29.05.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Further Reading: How do analysts define an oversold condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.